CAFFEINE CITRATE INJECTION USP SOLUTION

Страна: Канада

Език: английски

Източник: Health Canada

Активна съставка:

CAFFEINE CITRATE

Предлага се от:

OMEGA LABORATORIES LIMITED

АТС код:

N06BC01

INN (Международно Name):

CAFFEINE

дозиране:

20MG

Лекарствена форма:

SOLUTION

Композиция:

CAFFEINE CITRATE 20MG

Начин на приложение:

INTRAVENOUS

Броя в опаковка:

15G/50G

Вид предписание :

Prescription

Каталог на резюме:

Active ingredient group (AIG) number: 0162054001; AHFS:

Статус Оторизация:

APPROVED

Дата Оторизация:

2022-04-25

Данни за продукта

Product Monograph (Caffeine Citrate Injection USP)
Page 1 of 25
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
CAFFEINE CITRATE INJECTION USP
SOLUTION, 20 MG / ML, INTRAVENOUS / ORAL
(EACH ML CONTAINS 20 MG CAFFEINE CITRATE, EQUIVALENT TO 10 MG CAFFEINE
BASE)
USP
PSYCHOANALEPTICS, XANTHINE DERIVATIVES ATC CODE: N06BC01
OMEGA LABORATORIES LIMITED
11 177 HAMON STREET
MONTREAL, QUEBEC
H3M 3E4
DATE OF INITIAL APPROVAL:
April 20, 2022
Submission
Control No: 251391
Product Monograph (Caffeine Citrate Injection USP)
Page 2 of 25
TABLE OF
CONTENTS............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................... 4
1
INDICATIONS
................................................................................................................
4
1.1 Pediatrics
.....................................................................................................................
4
1.2 Geriatrics
.....................................................................................................................
4
2
CONTRAINDICATIONS................................................................................................
4
3
SERIOUS WARNINGS AND PRECAUTIONS
BOX..................................................... 5
4
DOSAGE AND ADMINISTRATION
.............................................................................
5
4.1 Dosing Considerations
.................................................................................................
5
4.2 Recommended Dose and Dosage
Adjustment................................................................
5
4.3 Administration
.............................................................................................................
7
5
OVERDOSAGE...............................................................................................................
8
6
DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING.............